Shots:

• The P-III ELOQUENT-1 study involves assessing of Empliciti (elotuzumab)+ Revlimid (lenalidomide) and dexamethasone (ERd) vs Rd in transplant-ineligible patients with newly diagnosed- previously untreated MM
• The P-III ELOQUENT-1 study resulted in not meeting its 1EPs of PFS while the safety profile of ERd is consistent with its known profiles
• Empliciti is an immunostimulatory Ab targeting SLAMF7 and has received the FDA’s approval in 2015 as a combination therapy with Rd for MM patients prior treated with one to three therapies and in 2018 approved as EPd combination therapy for MM patients prior treated with two therapies

Click here ­to­ read full press release/ article 

Ref: BMS | Image: BMS